Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Chongqing Zhifei Biological Products (300122 CH)
Watchlist
93
Analysis
Health Care
•
China
Chongqing Zhifei Biological Products Company Ltd. researches, manufactures, and sells vaccines and biological products including prevention products, blood products, diagnostic reagents, and therapeutic agents.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
23 Oct 2022 09:24
China Healthcare Weekly (Oct.21) - Electrophysiology VBP; Orthodontics VBP New Progress; HPV Vaccine
Unlike others' optimism,we see potential concerns in electrophysiology VBP; Orthodontics VBP is beyond expectation since invisible braces are...
Xinyao (Criss) Wang
Follow
304 Views
Share
bullish
•
CanSino Biologics
•
19 Oct 2022 08:51
CanSino Biologics Inc (688185.CH/6185.HK) - Some Positive Progress in Business
Cansino has made positive progress in commercialization and R&D recently. We look forward to the performance of MCV4 in H2. Its valuation in HKEX...
Xinyao (Criss) Wang
Follow
228 Views
Share
bearish
•
Thematic (Sector/Industry)
•
12 Oct 2022 08:24
Russia-Ukraine War Episode 2 - The Balance Could Tilt Again and Its Impact on Healthcare Industry
The first episode of Russia-Ukraine war has ended and entered a new phase.As it becomes "small world war",the balance may tilt again. It's also a...
Xinyao (Criss) Wang
Follow
230 Views
Share
bearish
•
Thematic (Sector/Industry)
•
09 Oct 2022 08:58
China Healthcare Weekly (Oct.7)- Biotech Accept Reality, Import Substitution Logic, Consumer Medical
Although unwilling, biotech will face the harshest truth in 2023; Import substitution isn't good logic. Investors should know "when to join" &...
Xinyao (Criss) Wang
Follow
263 Views
Share
bearish
•
AIM Vaccine
•
03 Oct 2022 08:42
Pre-IPO AIM Vaccine - AIM Is Overvalued, with Uncompetitive Pipeline and Challenging Outlook
AIM's products/pipeline are lack of competitiveness due to fierce competition and product upgrading, with gloomy outlook. Although the issue price...
Xinyao (Criss) Wang
Follow
216 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.9
x